Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Fiche publication
Date publication
janvier 2017
Journal
British journal of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FAVIER Laure, Dr KAMINSKY Marie-Christine
Tous les auteurs :
Heudel PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, Roche-Forestier S, Meunier J, Foa C, You B, Priou F, Tazi Y, Floquet A, Selle F, Berton-Rigaud D, Lesoin A, Kalbacher E, Lortholary A, Favier L, Treilleux I, Ray-Coquard I
Lien Pubmed
Résumé
Backround:Patients with metastatic endometrial carcinoma have a poor prognosis and PIK3CA mutations and amplifications are common in these cancers. This study evaluated the efficacy and safety of the pure PI3K inhibitor BKM120 in advanced or recurrent endometrial carcinoma.
Référence
Br. J. Cancer. 2017 Jan;116(3):303-309